Fractyl Health (NASDAQ:GUTS) CFO Weber Lara Smith Purchases 20,000 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) CFO Weber Lara Smith bought 20,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was purchased at an average price of $0.69 per share, for a total transaction of $13,800.00. Following the acquisition, the chief financial officer directly owned 20,000 shares of the company’s stock, valued at approximately $13,800. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Fractyl Health Stock Down 0.9%

Shares of Fractyl Health stock opened at $0.66 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. Fractyl Health, Inc. has a 52-week low of $0.38 and a 52-week high of $2.90. The stock has a market capitalization of $105.36 million, a price-to-earnings ratio of -0.51 and a beta of 2.34. The company’s 50 day moving average price is $0.67 and its 200-day moving average price is $1.08.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. Equities research analysts forecast that Fractyl Health, Inc. will post -0.6 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.40.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. FNY Investment Advisers LLC purchased a new position in Fractyl Health during the third quarter valued at $31,000. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the 2nd quarter worth about $31,000. Accredited Investors Inc. purchased a new position in shares of Fractyl Health in the 1st quarter worth about $46,000. Scientech Research LLC purchased a new position in shares of Fractyl Health in the 3rd quarter worth about $49,000. Finally, Prelude Capital Management LLC purchased a new position in shares of Fractyl Health in the 3rd quarter worth about $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.